Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Spectral Medical ( (TSE:EDT) ) is now available.
Spectral Medical and Vantive reported that full results from the Phase 3 Tigris trial of Polymyxin B Hemoadsorption in adults with endotoxic septic shock have been published in The Lancet Respiratory Medicine, confirming statistically robust survival benefits. The study showed a 10.3% absolute reduction in 28‑day mortality and a 15.5% reduction at 90 days after adjustment for baseline severity, with corresponding numbers needed to treat of 9.7 and 6.5 and a safety profile comparable to standard care.
The U.S. multicenter trial enrolled 157 high‑risk patients with endotoxic septic shock identified via the Endotoxin Activity Assay and randomized them 2:1 to PMX plus standard care or standard care alone. Using a Bayesian design aligned with FDA guidance, the trial achieved a 95.3% probability of benefit at 28 days and 99.4% at 90 days, potentially strengthening Spectral’s and Vantive’s positioning in critical care as they advance targeted therapies for a condition with millions of cases annually and no specific approved treatments in the U.S.
The most recent analyst rating on (TSE:EDT) stock is a Buy with a C$3.50 price target. To see the full list of analyst forecasts on Spectral Medical stock, see the TSE:EDT Stock Forecast page.
Spark’s Take on EDT Stock
According to Spark, TipRanks’ AI Analyst, EDT is a Neutral.
The score is weighed down primarily by weak financial performance—large ongoing losses, persistent cash burn, negative equity, and rising debt—implying high funding risk. Technicals are moderately supportive with mild positive momentum, but valuation remains constrained by negative earnings and no dividend data.
To see Spark’s full report on EDT stock, click here.
More about Spectral Medical
Spectral Medical Inc., listed on the TSX, is a late‑stage theranostic company focused on advancing therapeutic options for sepsis and septic shock using diagnostics like the FDA‑cleared Endotoxin Activity Assay. Its partner Vantive develops vital organ therapies aimed at novel diagnostic and treatment approaches for organ failure in critically ill patients worldwide.
Average Trading Volume: 45,830
Technical Sentiment Signal: Buy
Current Market Cap: C$389.1M
Find detailed analytics on EDT stock on TipRanks’ Stock Analysis page.